EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudiePragmatische StudieOpen Access · CC BY 4.0

Cost‐Effectiveness of rTMS as a Next Step in Antidepressant Non‐Responders: A Randomized Comparison With Current Antidepressant Treatment Approaches

Iris Dalhuisen iD, Kim Bui, Anne Kleijburg, Iris van Oostrom, Jan Spijker, Eric van Exel, Hans van Mierlo, Dieuwertje de Waardt, Martijn Arns, Indira Tendolkar, Philip van Eijndhoven, Ben Wijnen

Acta Psychiatrica Scandinavica · 2025-05 · 151 (5) · 613-624

DOI: 10.1111/acps.13782 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Psychiatrica Scandinavica, online erschienen am 22.12.2024. Verfasst von Iris Dalhuisen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Transcranial Magnetic Stimulation, Cost-Benefit Analysis, Depressive Disorder, Treatment-Resistant, Antidepressive Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, Netherlands Organization for Health Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although repetitive transcranial magnetic stimulation (rTMS) is an effective and commonly used treatment option for treatment‐resistant depression, its cost‐effectiveness remains much less studied. In particular, the comparative cost‐effectiveness of rTMS and other treatment options, such as antidepressant medication, has not been investigated.

Methods

An economic evaluation with 12 months follow‐up was conducted in the Dutch care setting as part of a pragmatic multicenter randomized controlled trial, in which patients with treatment‐resistant depression were randomized to treatment with rTMS or treatment with the next pharmacological step according to the treatment algorithm. Missing data were handled with single imputations using predictive mean matching (PMM) nested in bootstraps. Incremental cost‐effectiveness and cost‐utility ratios (ICERs/ICURs) were calculated, as well as cost‐effectiveness planes and cost‐effectiveness acceptability curves (CEACs).

Results

Higher QALYs, response, and remission rates were found for lower costs when comparing the rTMS group to the medication group. After 12 months, QALYs were 0.618 in the rTMS group and 0.545 in the medication group. The response was 27.1% and 24.4% and remission was 25.0% and 17.1%, respectively. Incremental costs for rTMS were −€2.280, resulting in a dominant ICUR for QALYs and ICER for response and remission. Conclusion rTMS appears to be a cost‐effective treatment option for treatment‐resistant depression when compared to the next pharmacological treatment step. The results support the implementation of rTMS as a step in the treatment algorithm for depression. Trial Registration The trial is registered within the Netherlands Trial Register (code: NL7628, date: March 29, 2019)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcranial Magnetic StimulationCost-Benefit AnalysisDepressive Disorder, Treatment-ResistantAntidepressive AgentsHumansFemaleMaleMiddle AgedAdultNetherlandsQuality-Adjusted Life Years

Stichwörter der Autor:innen

RCTantidepressantscost‐effectivenessmajor depressive disorderrTMS

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Donders Institute for Brain Cognition and Behavior, Centre for Medical Neuroscience, Nijmegen, The Netherlands.
  • Department of Health Sciences, Faculty of Earth and Life Sciences, VU University, Amsterdam, The Netherlands.
  • Center for Economic Evaluation, Trimbos Institute - Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands.
  • Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.
  • Neurocare Clinics, Nijmegen, The Netherlands.

ORCID-Profile: Iris Dalhuisen

Förderung

  • ZonMw
  • Netherlands Organization for Health Research and Development

Zitieren

APA

Dalhuisen, I., Bui, K., Kleijburg, A., van Oostrom, I., Spijker, J., van Exel, E., van Mierlo, H., de Waardt, D., Arns, M., Tendolkar, I., van Eijndhoven, P., & Wijnen, B. (2025). Cost‐Effectiveness of rTMS as a Next Step in Antidepressant Non‐Responders: A Randomized Comparison With Current Antidepressant Treatment Approaches. Acta Psychiatrica Scandinavica, 151(5), 613-624. https://doi.org/10.1111/acps.13782

Vancouver

Dalhuisen I, Bui K, Kleijburg A, van Oostrom I, Spijker J, van Exel E, et al. Cost‐Effectiveness of rTMS as a Next Step in Antidepressant Non‐Responders: A Randomized Comparison With Current Antidepressant Treatment Approaches. Acta Psychiatrica Scandinavica. 2025;151(5):613-624. doi:10.1111/acps.13782

BibTeX
@article{Dalhuisen2025,
  author = {Dalhuisen, Iris and Bui, Kim and Kleijburg, Anne and van Oostrom, Iris and Spijker, Jan and van Exel, Eric and van Mierlo, Hans and de Waardt, Dieuwertje and Arns, Martijn and Tendolkar, Indira and van Eijndhoven, Philip and Wijnen, Ben},
  title = {Cost‐Effectiveness of rTMS as a Next Step in Antidepressant Non‐Responders: A Randomized Comparison With Current Antidepressant Treatment Approaches},
  journal = {Acta Psychiatrica Scandinavica},
  year = {2025},
  volume = {151},
  number = {5},
  pages = {613--624},
  doi = {10.1111/acps.13782}
}
Kostenlos starten →